Management and Clinical Outcomes of Patients with Advanced Ovarian Cancer in Routine Clinical Practice in Spain: The OVOC Study
This study provides real-world data on therapeutic management and outcomes in AOC patients in Spain. A longer PFS was achieved in patients receiving targeted therapies. BRCA1/2 mutations were a favorable prognostic factor for PFS and BRCA2 mutation for OS.
Authors
- Diego Soto de Prado-Otero
- Alejandro Gallego (ORCID: https://orcid.org/0000-0002-5556-0449)
- Maria-Pilar Barretina-Ginesta (ORCID: https://orcid.org/0000-0003-0074-6614)
- Antonio González‐Martín (ORCID: https://orcid.org/0000-0003-0276-0778)
- Yolanda García García (ORCID: https://orcid.org/0000-0002-0280-4382)
- María Quindós-Varela (ORCID: https://orcid.org/0000-0001-9555-437X)
- Purificación Estévez-García (ORCID: https://orcid.org/0000-0002-4813-5145)
- María Jesús Rubio (ORCID: https://orcid.org/0000-0003-3682-3597)
- Eva Guerra
- Pilar Borraz
Institutions
- Hospital Universitario La Paz (ES)
- Institut Català d'Oncologia (ES)
- Hospital Universitario Reina Sofía (ES)
- Instituto de Biomedicina de Sevilla (ES)
- Clinica Universidad de Navarra (ES)
- Institute of Research and Innovation Parc Tauli (ES)
- Roche (Spain) (ES)
- Hospital Clínico Universitario de Valladolid (ES)
- Instituto de Investigación Biomédica de A Coruña (ES)
- Hospital Universitario Ramón y Cajal (ES)
Publication Details
- Journal
- Oncology and Therapy
- Published
- 2025-05-20
- DOI
- https://doi.org/10.1007/s40487-025-00347-1
- Primary Topic
- Ovarian cancer diagnosis and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Roche España